Biotricity, Inc. (BTCY) Stock Analysis

Biotricity, Inc. (BTCY) Healthcare & Pipeline Overview

Biotricity, Inc. delivers remote biometric data monitoring solutions, primarily in the United States, focusing on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Its Bioflux mobile cardiac telemetry solution and ECG analysis software position it in the competitive medical device market, serving medical, healthcare, and consumer segments.

What Is the Investment Thesis for BTCY?

Biotricity operates in the expanding remote patient monitoring market, driven by an aging population and increasing prevalence of chronic diseases. The company's Bioflux solution and ECG analysis software offer a comprehensive approach to cardiac monitoring, potentially reducing hospital readmissions and improving patient care. With a market capitalization of $0.01 billion, Biotricity's growth hinges on expanding its market share and securing regulatory approvals for new products. A gross margin of 81.1% indicates strong pricing power, but profitability remains a challenge with a negative P/E ratio of -1.83 and a negative profit margin of -26.0%. Key value drivers include increasing adoption of remote monitoring technologies, strategic partnerships with healthcare providers, and successful commercialization of its product pipeline. Investors should monitor the company's ability to achieve profitability and manage its cash flow effectively.

Based on FMP financials and quantitative analysis

BTCY Key Highlights

Market Cap of $0.01 billion reflects its position as a micro-cap company.

• Gross Margin of 81.1% indicates strong potential for profitability if sales volume increases.
• Negative P/E ratio of -1.83 suggests the company is currently not profitable.
• Profit Margin of -26.0% highlights the need for improved cost management and revenue growth.
• Beta of 1.40 indicates higher volatility compared to the overall market.

Who Are BTCY's Competitors?

BTCY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BTCY's Key Strengths?

Proprietary Bioflux mobile cardiac telemetry solution.

• ECG analysis software provides actionable insights.
• Focus on remote monitoring aligns with market trends.
• High gross margin of 81.1%.

What Are BTCY's Weaknesses?

Negative P/E ratio indicates lack of profitability.

• Limited market share compared to larger competitors.
• Reliance on a single product line (Bioflux).
• OTC market listing may limit investor access.

What Could Drive BTCY Stock Higher?

Expansion of Bioflux sales into new geographic markets.

• Development of new remote monitoring solutions for other chronic conditions.
• Strategic partnerships with healthcare providers to integrate Bioflux into their workflows.
• Potential FDA approval for new product features or enhancements.
• Integration of Bioflux with telehealth platforms to expand reach.

What Are the Key Risks for BTCY?

Financial-distress signal — its Altman Z-Score of -36.19 sits in the distress zone (elevated bankruptcy risk).

• Competition from larger, more established medical device companies.
• Regulatory hurdles and delays in FDA approval processes.
• Reimbursement challenges from insurance providers for remote monitoring services.
• Dependence on a single product line (Bioflux).
• Limited financial resources to support growth initiatives.

What Are the Growth Opportunities for BTCY?

• Expansion of Bioflux into New Markets: Biotricity has the opportunity to expand the market reach of its Bioflux mobile cardiac telemetry solution beyond the United States. The global remote patient monitoring market is projected to reach $175.2 billion by 2027, presenting a significant opportunity for Biotricity to increase its revenue streams. This expansion could involve strategic partnerships with international distributors and adaptation of the Bioflux solution to meet local regulatory requirements. Timeline: 2-3 years.
• Development of New Remote Monitoring Solutions: Biotricity can leverage its expertise in biometric data monitoring to develop new remote monitoring solutions for other chronic conditions, such as diabetes and respiratory diseases. The market for remote monitoring of diabetes is expected to grow significantly in the coming years, driven by the increasing prevalence of the disease. By diversifying its product portfolio, Biotricity can reduce its reliance on cardiac monitoring and tap into new revenue streams. Timeline: 3-5 years.
• Strategic Partnerships with Healthcare Providers: Biotricity can form strategic partnerships with healthcare providers, such as hospitals and clinics, to integrate its Bioflux solution into their existing workflows. These partnerships can provide Biotricity with access to a large patient base and increase the adoption of its products. The healthcare industry is increasingly embracing remote patient monitoring as a way to improve patient outcomes and reduce costs. Timeline: Ongoing.
• Integration with Telehealth Platforms: Biotricity can integrate its Bioflux solution with telehealth platforms to provide patients with remote access to healthcare professionals. The telehealth market is experiencing rapid growth, driven by the increasing demand for convenient and accessible healthcare services. By integrating with telehealth platforms, Biotricity can expand its reach and provide patients with a more comprehensive healthcare experience. Timeline: 1-2 years.
• Leveraging AI and Machine Learning: Biotricity can leverage artificial intelligence (AI) and machine learning (ML) to enhance its ECG analysis software and provide more accurate and personalized insights to healthcare professionals. AI and ML can be used to identify patterns in patient data and predict potential health issues before they occur. This can improve patient outcomes and reduce the burden on healthcare systems. Timeline: Ongoing.

What Are BTCY's Competitive Advantages?

• Proprietary ECG analysis software.
• Integrated Bioflux mobile cardiac telemetry solution.
• Focus on remote monitoring solutions for chronic illnesses.
• Established relationships with healthcare providers.

What Does BTCY Do?

Biotricity, Inc., established as a medical technology company, specializes in biometric data monitoring solutions within the United States. The company's core mission revolves around providing remote monitoring solutions tailored for medical, healthcare, and consumer markets, with a particular emphasis on diagnostic and post-diagnostic applications for lifestyle-related and chronic illnesses. Biotricity's flagship product is the Bioflux mobile cardiac telemetry solution, an integrated ECG device designed for continuous heart monitoring. Complementing this hardware is their proprietary ECG analysis software, which analyzes and synthesizes patient ECG monitoring data to provide actionable insights for healthcare professionals. The company's solutions aim to improve patient outcomes and reduce healthcare costs through proactive monitoring and early detection of potential health issues. Headquartered in Redwood City, California, Biotricity is strategically located in a hub of technological innovation, allowing it to attract talent and foster partnerships within the medical technology ecosystem. The company continues to evolve its product offerings to address the growing demand for remote patient monitoring solutions.

What Products and Services Does BTCY Offer?

• Develop and market the Bioflux mobile cardiac telemetry solution.
• Provide ECG analysis software for synthesizing patient ECG monitoring data.
• Offer remote monitoring solutions for medical, healthcare, and consumer markets.
• Focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.
• Provide solutions for continuous heart monitoring.
• Offer software components for analyzing ECG data.

How Does BTCY Make Money?

• Sales of Bioflux mobile cardiac telemetry devices.
• Subscription fees for ECG analysis software.
• Partnerships with healthcare providers for remote patient monitoring services.

What Industry Does BTCY Operate In?

Biotricity operates within the medical device industry, specifically in the remote patient monitoring (RPM) market. This market is experiencing rapid growth, driven by factors such as the aging population, increasing prevalence of chronic diseases, and advancements in wearable technology. The competitive landscape includes established medical device companies and emerging technology startups. Biotricity's focus on cardiac monitoring positions it within a niche segment of the RPM market. The industry is also subject to stringent regulatory requirements, including FDA approvals and data privacy regulations.

Who Are BTCY's Key Customers?

• Hospitals and clinics.
• Healthcare providers.
• Patients with chronic illnesses.
• Consumers seeking remote health monitoring solutions.

Company Profile

Biotricity, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Waqaas Al-Siddiq. BTCY has traded publicly since 2018.

Biotricity, Inc. Financial Trajectory

Biotricity, Inc. (BTCY) reported $4.3M in revenue for Jun 2026, reflecting 0.6% growth compared to the prior quarter. The company recorded a net loss of $959K, with diluted EPS of $-0.04. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this unknown Healthcare company. Across the four most recent quarters, BTCY averaged $-0.03 in diluted EPS.

Return on equity for Biotricity, Inc. stands at 12.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -70.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -30.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.21 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -112.8%, the inverse of the P/E and a quick read on earnings relative to price.

Biotricity, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -36.19 places it in the distress zone, a signal of elevated financial risk.

Biotricity, Inc. has beaten Wall Street's EPS estimate in 7 of its last 7 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 66.8% above estimates on average.

Wall Street analysts project Biotricity, Inc. revenue of about $15.8M for fiscal 2026, with EPS near $-0.32.

The most recent 10 insider filings for Biotricity, Inc. break down as 0 sales and 10 purchases. On net that is roughly 2.3M shares acquired (about $2.5M) — insiders putting money in tends to read as conviction.

BTCY Financials

BTCY Latest News

BTCY Analyst Consensus

BTCY MoonshotScore

BTCY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources